Sarepta increases incentive plan shares by 500,000; all director nominees elected at annual meeting

Sarepta Therapeutics, Inc.

Board approved amendment to 2024 Employment Commencement Incentive Plan, increasing share reserve by 500,000 to 6,185,308 shares.
At June 6 annual meeting, all four Class I director nominees (Douglas Ingram, Hans Wigzell, Kathryn Boor, Michael Chambers) were elected.
Advisory say-on-pay proposal passed with approximately 63.6 million votes for and 9.0 million against.
Stockholders ratified KPMG as independent auditor for 2024; approximately 77.1 million votes in favor.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.